Terumo Cardiovascular Group

e-mail usprint

Surface Coating

A Terumo survey of 300 U.S. chief perfusionists found that 74% used biocompatible coatings. Xcoating frequently referred to in scientific literature by its chemical name, PMEA, is Terumo's amphiphilic, biopassive coating.

Information provided on this website is not intended to make claims that the products are safe and effective for any use other than those explicitly described in the Instructions for Use. Clinicians should refer to the Instructions for Use or Owner's Manuals for complete information on the intended use of any product mentioned in this website.

CASE STUDY: Bloodless Cardiac Surgery is a Team Sport
Ninety percent of patients weighing over 25 kilos have surgery without receiving blood at The Heart Center at Nationwide Children's Hospital in Columbus, Ohio. Read about its blood management program.

ABSTRACT: Investigation of Blood Compatibility of PMEA-Coated Extracorporeal Circuits. Journal of Bioactive and Compatible Polymers, Vol 17, Sept 2002. Kocakulak M, et al.
In a study comparing PMEA-coated and uncoated oxygenators, the authors found greater retention of clotting factors and platelets and less post-op hemorrhaging when using PMEA-coated oxygenators.

ABSTRACT: Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic CPB. Cardiovascular and Hematological Agents. 2004; Vol. 2:No 4. Gunaydin S, et al.
The authors compare surface coatings, including Xcoating, in 155 CPB cases for chemical composition, biomaterial evaluation and clinical efficacy.

ABSTRACT: The CAPIOX RX05 Oxygenator: Pediatric Clinical Observations. Perfusion. 2003;18, 321-323, Tinius, et al.
The authors provide clinical observations on the use of the CAPIOX® BABY RX™ Oxygenator and reducing prime volume in neonate circuits.

ABSTRACT: Effects of New Polymer-Coated Extracorporeal Circuits on Biocompatibility During Cardiopulmonary Bypass. Artificial Organs, Volume 24, No 7, 2000. Saito, et al.
This study compares Xcoating™ to heparin coating in reducing the release of bradykinin and leukocyte activation during CPB.

ABSTRACT: Biocompatibility of Poly (2-methoxyethylacrylate) Coating for Cardiopulmonary Bypass. Annals Thoracic Cardiovascular Surgery, 2003, Volume 9, No 1. Noguchi, et al.
The authors compare the biocompatibility of PMEA-coated and heparin-coated circuits by measuring several inflammatory markers. Results indicate PMEA-coated circuits are as biocompatible as heparin coated circuits.

ABSTRACT: Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and Xcoating provides clinically significant benefits for high risk patients.

ABSTRACT: Xcoating: A New Biopassive Polymer Coating. Canadian Perfusion Canadienne, Volume 11, No 2, June 2001. Schiel, et al.
This paper explains the mechanism and benefits of Xcoating.